AstraZeneca's Imfinzi shows positive response in gastric cancers
peterschreiber.media         
Top-level phase 3 data on AstraZeneca's Imfinzi (durvalumab) showed statistically significant improvement in pathologic complete response compared to neoadjuvant chemotherapy alone in gastric and gastroesophageal junction cancers.
The MATTERHORN trial is continuing to determine event-free survival and overall survival.

In the trial, Imfinzi was added toÂ standard-of-care chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) before surgery.